FDA Pulls GlaxoSmithKline’s Antibody Drug as Omicron Subvariant BA.2 Dominates U.S. COVID-19 Cases
GlaxoSmithKline’s IV drug for COVID-19 should no longer be used because it is likely ineffective against the Omicron subvariant BA.2 that now accounts for most